Unison Medicines A new era of infection control References Full PDF

Acknowledgments

We thank Liz Yoo, Kathy Drake, Dr. Greg Makoff, Dr. Lionel Chia, Alice Witt, Dr. Kenneth Lam, Conna Weiner, Shauna Holiman, Dr. Jeff Marsh and Dr. Jason Valadao for kindly reviewing several drafts of this essay and providing essential and insightful critique.

References

  1. 1Murray, C. J. et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet S0140673621027240 (2022) doi:10.1016/S0140-6736(21)02724-0.
  2. 2O’Neill, J. TACKLING DRUG-RESISTANT INFECTIONS GLOBALLY: FINAL REPORT AND RECOMMENDATIONS. (2016).
  3. 3Evans, E. J., Meyer, A. & Conti, R. M. Sizing A Market Entry Reward for the Development of New Antibiotics. Mossavar-Rahmani Center for Business & Government Associate Working Paper Series https://www.hks.harvard.edu/sites/default/files/centers/mrcbg/Final_AWP_232.pdf.
  4. 4Evans, E. J., Witt, P. D., Zhanel, G. G. & Klein, D. J. Rethinking the unmet need for novel antibiotics. J Antibiot 79, 227–230 (2026).
  5. 5Foxman, B., Barlow, R., D’Arcy, H., Gillespie, B. & Sobel, J. D. Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol 10, 509–515 (2000).
  6. 6Foxman, B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. The American Journal of Medicine 113, 5–13 (2002).
  7. 7Butler, C. C., Hawking, M. K., Quigley, A. & McNulty, C. A. Incidence, severity, help seeking, and management of uncomplicated urinary tract infection: a population-based survey. Br J Gen Pract 65, e702–e707 (2015).
  8. 8Mulvey, M. A. et al. Induction and Evasion of Host Defenses by Type 1–Piliated Uropathogenic Escherichia coli.
  9. 9Justice, S. S. et al. Differentiation and developmental pathways of uropathogenic Escherichia coli in urinary tract pathogenesis. Proc. Natl. Acad. Sci. U.S.A. 101, 1333–1338 (2004).
  10. 10Blango, M. G. & Mulvey, M. A. Persistence of Uropathogenic Escherichia coli in the Face of Multiple Antibiotics. Antimicrob Agents Chemother 54, 1855–1863 (2010).
  11. 11Swamy, S. et al. Recalcitrant chronic bladder pain and recurrent cystitis but negative urinalysis: What should we do? Int Urogynecol J 29, 1035–1043 (2018).
  12. 12De Nisco, N. J. et al. Direct Detection of Tissue-Resident Bacteria and Chronic Inflammation in the Bladder Wall of Postmenopausal Women with Recurrent Urinary Tract Infection. Journal of Molecular Biology 431, 4368–4379 (2019).
  13. 13Lau, W. K. et al. Novel Particles Conferring Eradication of Deep Tissue Bacterial Reservoirs for the Treatment of Chronic Urinary Tract Infection.
  14. 14Armstrong, S. V., Malik, A. A., Alhalabi, F. & Zimmern, P. Urinary Tract Infection (UTI)-free and Recurrent UTI (rUTI)-Free Survivals Following Bladder Electrofulguration in Women With a History of Antibiotic-Refractory rUTI.
  15. 15Lukaszewski, R. A. et al. Pathogenesis of Yersinia pestis Infection in BALB/c Mice: Effects on Host Macrophages and Neutrophils. Infect Immun 73, 7142–7150 (2005).
  16. 16Celli, J. & Zahrt, T. C. Mechanisms of Francisella tularensis Intracellular Pathogenesis. Cold Spring Harbor Perspectives in Medicine 3, a010314–a010314 (2013).
  17. 17Whitlock, G. C. et al. Burkholderia mallei cellular interactions in a respiratory cell model. Journal of Medical Microbiology 58, 554–562 (2009).
  18. 18Jones, A. L., Beveridge, T. J. & Woods, D. E. Intracellular survival of Burkholderia pseudomallei. Infect Immun 64, 782–790 (1996).
  19. 19Guidi-Rontani, C. The alveolar macrophage: the Trojan horse of Bacillus anthracis. Trends in Microbiology 10, 405–409 (2002).
  20. 20Routy, B. et al. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. Science 359, 91–97 (2018).
  21. 21Stein-Thoeringer, C. K. et al. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nat Med 29, 906–916 (2023).
  22. 22Hebert, A., Sayasith, K., Senechal, S., Dubreuil, P. & Lagace, J. Demonstration of intracellular Staphylococcus aureus in bovine mastitis alveolar cells and macrophages isolated from naturally infected cow milk. FEMS Microbiology Letters 193, 57–62 (2000).
  23. 23Karuppannan, A. K. & Opriessnig, T. Lawsonia intracellularis: Revisiting the Disease Ecology and Control of This Fastidious Pathogen in Pigs. Front. Vet. Sci. 5, 181 (2018).
  24. 24Rozas-Serri, M. Why Does Piscirickettsia salmonis Break the Immunological Paradigm in Farmed Salmon? Biological Context to Understand the Relative Control of Piscirickettsiosis. Front. Immunol. 13, 856896 (2022).
  25. 25Cabello, F. C., Millanao, A. & Godfrey, H. P. Piscirickettsia salmonis pathogenicity: using the damage-response framework to look beyond smoke and mirrors. mBio 16, e03821-24 (2025).
  26. 26Huang, W. et al. Bacterial Vector-Borne Plant Diseases: Unanswered Questions and Future Directions. Molecular Plant 13, 1379–1393 (2020).
  27. 27USDA, E. R. S. Fruit and Tree Nuts Data - Fruit and Tree Nuts Yearbook Tables. Citrus Fruit file (Tables C-1-C-20) https://www.ers.usda.gov/data-products/fruit-and-tree-nuts-data/fruit-and-tree-nuts-yearbook-tables.
  28. 28Ma, W. et al. Citrus Huanglongbing is a pathogen-triggered immune disease that can be mitigated with antioxidants and gibberellin. Nat Commun 13, 529 (2022).
  29. 29Irigoyen, S. et al. Plant hairy roots enable high throughput identification of antimicrobials against Candidatus Liberibacter spp. Nat Commun 11, 5802 (2020).
  30. 30Metlay, J. P. & Waterer, G. W. Diagnosis and Treatment of Adults With Community-Acquired Pneumonia. Am J Respir Crit Care Med Vol 200, e45–e67 (2019).
  31. 31Davies, S. C., Grant, J. & Catchpole, M. The Drugs Don’t Work: A Global Threat. (Viking / Penguin Books, London, England, 2013).
  32. 32Klein, E. Y., Tseng, K. K., Pant, S. & Laxminarayan, R. Tracking global trends in the effectiveness of antibiotic therapy using the Drug Resistance Index. BMJ Glob Health 4, e001315 (2019).
  33. 33Naghavi, M. et al. Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. The Lancet 404, 1199–1226 (2024).
  34. 34Centers for Disease Control and Prevention (U.S.). Antibiotic Resistance Threats in the United States, 2019. https://stacks.cdc.gov/view/cdc/82532 (2019) doi:10.15620/cdc:82532.
  35. 35Piddock, L. J. V. et al. Advancing global antibiotic research, development and access. Nat Med 30, 2432–2443 (2024).
  36. 36Armstrong DG, Tan TW, Boulton AJM, & Bus SA. Diabetic Foot Ulcers: A Review. JAMA 330, 62–75 (2023).
  37. 37McDermott K, Fang M, Boulton AJM, Selvin E, & Hicks CW. Etiology, Epidemiology, and Disparities in the Burden of Diabetic Foot Ulcers. Diabetes Care 46, 209–221 (2023).
  38. 38Rice JB et al. Burden of Diabetic Foot Ulcers for Medicare and Private Insurers. Diabetes Care 37, 651–658 (2014).
  39. 39Hicks, C. W. et al. Burden of Infected Diabetic Foot Ulcers on Hospital Admissions and Costs. Annals of Vascular Surgery 33, 149–158 (2016).
  40. 40Miller, M., Knepper, B. & Young, H. Risk Factors Associated with 30-Day Readmission in Patients with Diabetic Foot Infections. Journal of the American Podiatric Medical Association 110, Article 1 (2020).
  41. 41Hicks, C. W. et al. Contribution of 30-day readmissions to the increasing costs of care for the diabetic foot. Journal of Vascular Surgery 70, 1263–1270 (2019).
  42. 42Ramirez, J. A. et al. Adults Hospitalized With Pneumonia in the United States: Incidence, Epidemiology, and Mortality. Clinical Infectious Diseases 65, 1806–1812 (2017).
  43. 43Jain S, Self WH, & Wunderink RG. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. New England Journal of Medicine 373, 415–427 (2015).
  44. 44Oster, G., Berger, A., Edelsberg, J. & Weber, D. J. Initial treatment failure in non-ICU community-acquired pneumonia: risk factors and association with length of stay, total hospital charges, and mortality. Journal of Medical Economics 16, 809–819 (2013).
  45. 45Menendez, R. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax 59, 960–965 (2004).
  46. 46Llop, C. J., Tuttle, E., Tillotson, G. S., LaPlante, K. & File, T. M. J. Antibiotic treatment patterns, costs, and resource utilization among patients with community acquired pneumonia: a US cohort study. Hospital Practice 45, 1–8 (2017).
  47. 47Vella V, Galgani I, & Polito L. The Incidence of Skin and Soft Tissue Infections in the United States and Associated Healthcare Utilization Between 2010 and 2020. Open Forum Infectious Diseases 11, ofae267 (2024).
  48. 48Miller, L. G. et al. Incidence of skin and soft tissue infections in ambulatory and inpatient settings, 2005-2010. BMC Infectious Diseases 15, 362 (2015).
  49. 49Labreche, M. J. et al. Treatment Failure and Costs in Patients With Methicillin-Resistant Staphylococcus aureus (MRSA) Skin and Soft Tissue Infections: A South Texas Ambulatory Research Network (STARNet) Study. The Journal of the American Board of Family Medicine 26, 508–517 (2013).
  50. 50Berger A, Oster G, & Edelsberg J. Initial Treatment Failure in Patients With Complicated Skin and Skin Structure Infections. Surgical Infections 14, 304–312 (2013).
  51. 51Carreno JJ, Tam IM, & Meyers JL. Longitudinal, Nationwide, Cohort Study to Assess Incidence, Outcomes, and Costs Associated With Complicated Urinary Tract Infection. Open Forum Infectious Diseases 6, ofz446 (2019).
  52. 52Lodise, T. P., Manjelievskaia, J., Marchlewicz, E. H. & Rodriguez, M. Retrospective Cohort Study of the 12-Month Epidemiology, Treatment Patterns, Outcomes, and Health Care Costs Among Adult Patients With Complicated Urinary Tract Infections. Open Forum Infectious Diseases 9, ofac307 (2022).
  53. 53Tillotson, G., Lodise, T., Classi, P., Mildvan, D. & McKinnell, J. A. Antibiotic Treatment Failure and Associated Outcomes Among Adult Patients With Community-Acquired Pneumonia in the Outpatient Setting: A Real-world US Insurance Claims Database Study. Open Forum Infectious Diseases 7, ofaa065 (2020).
  54. 54Hess G, Hill JW, & Raut MK. Comparative antibiotic failure rates in the treatment of community-acquired pneumonia: results from a claims analysis. Advances in Therapy 27, 743–755 (2010).
  55. 55Kollef, M. H., Hamilton, C. W. & Ernst, F. R. Economic Impact of Ventilator-Associated Pneumonia in a Large Matched Cohort. Infect. Control Hosp. Epidemiol. 33, 250–256 (2012).
  56. 56Kollef, M. H. et al. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 19, 1299–1311 (2019).
  57. 57Torres, A. et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. The Lancet Infectious Diseases 18, 285–295 (2018).
  58. 58Iregui, M., Ward, S., Sherman, G., Fraser, V. J. & Kollef, M. H. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 122, 262–268 (2002).
  59. 59Swenson, B. R., Metzger, R. & Hedrick, T. L. Economic consequences of failure of initial antibiotic therapy in hospitalized adults with complicated intra-abdominal infections. Surgical Infections 9, 335–347 (2008).
  60. 60Chong YP, Bae IG, & Lee SR. Clinical and Economic Consequences of Failure of Initial Antibiotic Therapy for Patients with Community-Onset Complicated Intra-Abdominal Infections. PLoS ONE 10, e0119956 (2015).
  61. 61U.S. Bureau of Labor Statistics. Consumer Price Index - Medical Care (series CUUR0000SAM / CPIMEDSL), 1982-84=100, annual averages. U.S. Bureau of Labor Statistics (2026).
  62. 62Jones BE, Sarvet AL, & Ying J. Incidence and Outcomes of Non-Ventilator-Associated Hospital-Acquired Pneumonia in 284 US Hospitals Using Electronic Surveillance Criteria. JAMA Network Open 6, e2314185 (2023).
  63. 63Giuliano, K. K. et al. Incidence, mortality, and cost trends in nonventilator hospital-acquired pneumonia in Medicaid beneficiaries, 2015-2019. American Journal of Infection Control 51, 227–230 (2023).
  64. 64Advani SD, Luck ME, & Chang R. Assessing the burden of outpatient urinary tract infections in the United States: analysis of nationwide ambulatory data (2016-2019). Antimicrobial Stewardship & Healthcare Epidemiology 5, e143 (2025).
  65. 65Franklin M, Emden MR, & Kautz S. Cost burden of patients with oral antibiotic treatment failure for uncomplicated urinary tract infection in the US. Open Forum Infectious Diseases 10, ofad500.2449 (2023).
  66. 66Fromer DL, Luck ME, & Cheng WY. Risk Factors for Empiric Treatment Failure in US Female Outpatients with Uncomplicated Urinary Tract Infection: An Observational Study. Journal of General Internal Medicine 40, 862–870 (2025).
  67. 67Ellis, J. J. et al. Impact of empirical treatment failure on health care resource utilization and costs among female patients with uncomplicated urinary tract infections in a US-based Integrated Health Delivery Network. Journal of Managed Care and Specialty Pharmacy 31, 879–889 (2025).
  68. 68Goto M & Al-Hasan MN. Overall burden of bloodstream infection and nosocomial bloodstream infection in North America and Europe. Clinical Microbiology and Infection 19, 501–509 (2013).
  69. 69Kadri SS, Lai YL, & Warner S. Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals. The Lancet Infectious Diseases 21, 241–251 (2021).
  70. 70Lodise, T. P., Kanakamedala, H., Hsu, W.-C. & Cai, B. Impact of Incremental Delays in Appropriate Therapy on the Outcomes of Hospitalized Adult Patients with Gram-negative Bloodstream Infections: Every day matters. Pharmacotherapy 40, 1176–1187 (2020).
  71. 71Ohnuma, T. et al. Association of Appropriate Empirical Antimicrobial Therapy With In-Hospital Mortality in Patients With Bloodstream Infections in the US. JAMA Network Open 6, e2249353 (2023).
  72. 72Thaden JT, Li Y, & Ruffin F. Increased Costs Associated with Bloodstream Infections Caused by Multidrug-Resistant Gram-Negative Bacteria Are Due Primarily to Patients with Hospital-Acquired Infections. Antimicrobial Agents and Chemotherapy 61, e01709-16 (2017).
  73. 73Goldstein E & Lipsitch M. The relation between prescribing of different antibiotics and rates of mortality with sepsis in US adults. BMC Infectious Diseases 20, 169 (2020).
  74. 74Goldstein E et al. Antimicrobial resistance prevalence, rates of hospitalization with septicemia and rates of mortality with sepsis in adults in different US states. International Journal of Antimicrobial Agents 54, 23–34 (2019).
  75. 75Goldstein E et al. Levels of outpatient prescribing for four major antibiotic classes and rates of septicemia hospitalization in adults in different US states - a statistical analysis. BMC Public Health 19, 1138 (2019).
  76. 76Romling U & Balsalobre C. Biofilm infections, their resilience to therapy and innovative treatment strategies. Journal of Internal Medicine 272, 541–561 (2012).
  77. 77Hall-Stoodley L, Costerton JW, & Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nature Reviews Microbiology 2, 95–108 (2004).
  78. 78Bjarnsholt T. The role of bacterial biofilms in chronic infections. APMIS Supplementum 121, 1–51 (2013).
  79. 79Novotny, L. A., Jurcisek, J. A., Goodman, S. D. & Bakaletz, L. O. Monoclonal antibodies against DNA-binding tips of DNABII proteins disrupt biofilms in vitro and induce bacterial clearance in vivo. eBioMedicine 10, 33–44 (2016).
  80. 80Novotny, L. A., Goodman, S. D. & Bakaletz, L. O. Targeting a bacterial DNABII protein with a chimeric peptide immunogen or humanised monoclonal antibody to prevent or treat recalcitrant biofilm-mediated infections. EBioMedicine 59, 102867 (2020).
  81. 81James GA, Swogger E, & Wolcott R. Biofilms in chronic wounds. Wound Repair and Regeneration 16, 37–44 (2008).
  82. 82Malone M, Bjarnsholt T, & McBain AJ. The prevalence of biofilms in chronic wounds: a systematic review and meta-analysis of published data. Journal of Wound Care 26, 20–25 (2017).
  83. 83Bjarnsholt T, Jensen PO, & Fiandaca MJ. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatric Pulmonology 44, 547–558 (2009).
  84. 84Hoiby, N., Ciofu, O. & Bjarnsholt. Pseudomonas aeruginosa biofilms in cystic fibrosis. Future Microbiology 5, (2010).
  85. 85Chai YH & Xu JF. How does Pseudomonas aeruginosa affect the progression of bronchiectasis? Clinical Microbiology and Infection 26, 313–318 (2020).
  86. 86Sanderson AR, Leid JG, & Hunsaker D. Bacterial biofilms on the sinus mucosa of human subjects with chronic rhinosinusitis. The Laryngoscope 116, 1121–1126 (2006).
  87. 87Masters EA, Trombetta RP, & de Mesy Bentley KL. Evolving concepts in bone infection: redefining ‘biofilm’, ‘acute vs. chronic osteomyelitis’, ‘the immune proteome’ and ‘local antibiotic therapy’. Bone Research 7, 20 (2019).
  88. 88Werdan K, Dietz S, & Loffler B. Mechanisms of infective endocarditis: pathogen-host interaction and risk states. Nature Reviews Cardiology 11, 35–50 (2014).
  89. 89Flores-Mireles AL, Walker JN, Caparon M, & Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nature Reviews Microbiology 13, 269–284 (2015).
  90. 90Costerton JW, Stewart PS, & Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 284, 1318–1322 (1999).
  91. 91Stewart PS & Costerton JW. Antibiotic resistance of bacteria in biofilms. The Lancet 358, 135–138 (2001).
  92. 92Pai M, Behr MA, & Dowdy D. Tuberculosis. Nature Reviews Disease Primers 2, 16076 (2016).
  93. 93Ramakrishnan L. Revisiting the role of the granuloma in tuberculosis. Nature Reviews Immunology 12, 352–366 (2012).
  94. 94Daley CL, Iaccarino JM, & Lange C. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clinical Infectious Diseases 71, e1–e36 (2020).
  95. 95Scollard DM et al. The continuing challenges of leprosy. Clinical Microbiology Reviews 19, 338–381 (2006).
  96. 96Masaki T et al. Reprogramming adult Schwann cells to stem cell-like cells by leprosy bacilli promotes dissemination of infection. Cell 152, 51–67 (2013).
  97. 97Crump JA, Sjolund-Karlsson M, Gordon MA, & Parry CM. Epidemiology, Clinical Presentation, Laboratory Diagnosis, Antimicrobial Resistance, and Antimicrobial Management of Invasive Salmonella Infections. Clinical Microbiology Reviews 28, 901–937 (2015).
  98. 98Crawford RW, Rosales-Reyes R, & Ramirez-Aguilar ML. Gallstones play a significant role in Salmonella spp. gallbladder colonization and carriage. Proceedings of the National Academy of Sciences USA 107, 4353–4358 (2010).
  99. 99Feasey NA, Dougan G, Kingsley RA, Heyderman RS, & Gordon MA. Invasive non-typhoidal salmonella disease: an emerging and neglected tropical disease in Africa. The Lancet 379, 2489–2499 (2012).
  100. 100Newton HJ, Ang DKY, van Driel IR, & Hartland EL. Molecular pathogenesis of infections caused by Legionella pneumophila. Clinical Microbiology Reviews 23, 274–298 (2010).
  101. 101Cunha BA, Burillo A, & Bouza E. Legionnaires’ disease. The Lancet 387, 376–385 (2016).
  102. 102Elwell C, Mirrashidi K, & Engel J. Chlamydia cell biology and pathogenesis. Nature Reviews Microbiology 14, 385–400 (2016).
  103. 103O’Connell CM & Ferone ME. Chlamydia trachomatis Genital Infections. Microbial Cell 3, 390–403 (2016).
  104. 104Roulis E, Polkinghorne A, & Timms P. Chlamydia pneumoniae: modern insights into an ancient pathogen. Trends in Microbiology 21, 120–128 (2013).
  105. 105Radoshevich L & Cossart P. Listeria monocytogenes: towards a complete picture of its physiology and pathogenesis. Nature Reviews Microbiology 16, 32–46 (2018).
  106. 106Charlier C, Perrodeau E, & Leclercq A. Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study. The Lancet Infectious Diseases 17, 510–519 (2017).
  107. 107Marth T, Moos V, Muller C, Biagi F, & Schneider T. Tropheryma whipplei infection and Whipple’s disease. The Lancet Infectious Diseases 16, e13–e22 (2016).
  108. 108Proctor RA, von Eiff C, & Kahl BC. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nature Reviews Microbiology 4, 295–305 (2006).
  109. 109Tuchscherr L, Medina E, & Hussain M. Staphylococcus aureus phenotype switching: an effective bacterial strategy to escape host immune response and establish a chronic infection. EMBO Molecular Medicine 3, 129–141 (2011).
  110. 110Osterlund A, Popa R, Nikkila T, Scheynius A, & Engstrand L. Intracellular reservoir of Streptococcus pyogenes in vivo: a possible explanation for recurrent pharyngotonsillitis. The Laryngoscope 107, 640–647 (1997).
  111. 111Kaplan EL, Chhatwal GS, & Rohde M. Reduced ability of penicillin to eradicate ingested group A streptococci from epithelial cells: clinical and pathogenetic implications. Clinical Infectious Diseases 43, 1398–1406 (2006).
  112. 112Glasser AL, Boudeau J, & Barnich N. Adherent invasive Escherichia coli strains from patients with Crohn’s disease survive and replicate within macrophages without inducing host cell death. Infection and Immunity 69, 5529–5537 (2001).
  113. 113Darfeuille-Michaud, A. et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease. Gastroenterology 127, 412–421 (2004).
  114. 114Demarre, G. et al. The Crohn’s disease-associated Escherichia coli strain LF82 relies on SOS and stringent responses to survive, multiply and tolerate antibiotics within macrophages. PLoS Pathog 15, e1008123 (2019).
  115. 115Fisher RA, Gollan B, & Helaine S. Persistent bacterial infections and persister cells. Nature Reviews Microbiology 15, 453–464 (2017).
  116. 116Levin-Reisman I et al. Antibiotic tolerance facilitates the evolution of resistance. Science 355, 826–830 (2017).
  117. 117Marshall JC, Maier RV, Jimenez M, & Dellinger EP. Source control in the management of severe sepsis and septic shock: an evidence-based review. Critical Care Medicine 32, S513–S526 (2004).
  118. 118Roberts JA, Paul SK, & Akova M. DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients? Clinical Infectious Diseases 58, 1072–1083 (2014).
  119. 119Unemo, M. & Shafer, W. M. Antimicrobial Resistance in Neisseria gonorrhoeae in the 21st Century: Past, Evolution, and Future. Clin Microbiol Rev 27, 587–613 (2014).
  120. 120Haney, E. F. & Hancock, R. E. W. Addressing Antibiotic Failure—Beyond Genetically Encoded Antimicrobial Resistance. Front. Drug. Discov. 2, 892975 (2022).
  121. 121de Nies, L., Kobras, C. M. & Stracy, M. Antibiotic-induced collateral damage to the microbiota and associated infections. Nature Reviews Microbiology 21, 789–804 (2023).
  122. 122Buffie, C. G., Bucci, V. & Stein, R. R. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517, 205–208 (2015).
  123. 123Caballero-Flores, G., Pickard, J. M. & Núñez, G. Microbiota-mediated colonization resistance: mechanisms and regulation. Nature Reviews Microbiology 21, 347–360 (2023).
  124. 124Guh, A. Y., Mu, Y. & Winston, L. G. Trends in U.S. burden of Clostridioides difficile infection and outcomes. New England Journal of Medicine 382, 1320–1330 (2020).
  125. 125Brown, K. A., Khanafer, N., Daneman, N. & Fisman, D. N. Meta-Analysis of Antibiotics and the Risk of Community-Associated Clostridium difficile Infection. Antimicrob Agents Chemother 57, 2326–2332 (2013).
  126. 126Li, H., Miao, M., Jia, C. & Yang, F. Interactions between Candida albicans and the resident microbiota. Frontiers in Microbiology 13, 930495 (2022).
  127. 127Xu, J., Schwebke, J. R. & Sobel, J. D. Effect of antibiotics on vulvovaginal candidiasis: a MetroNet study. Journal of the American Board of Family Medicine 21, 261–268 (2008).
  128. 128Ubeda, C., Taur, Y. & Jenq, R. R. Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. Journal of Clinical Investigation 120, 4332–4341 (2010).
  129. 129Griffin, A. J. & McSorley, S. J. Successful treatment of bacterial infection hinders development of acquired immunity. Journal of Immunology 183, 1263–1270 (2009).
  130. 130Benoun, J. M., Labuda, J. C. & McSorley, S. J. Collateral damage: detrimental effect of antibiotics on the development of protective immune memory. mBio 7, e01520-16 (2016).
  131. 131Kleinhenz, M., Beesetty, P., Yang, C., Li, Z. & Montgomery, C. P. Antibiotic treatment of Staphylococcus aureus infection inhibits the development of protective immunity. Antimicrobial Agents and Chemotherapy 66, e02270-21 (2022).
  132. 132Ansaldo, E., Farley, T. K. & Belkaid, Y. Control of immunity by the microbiota. Annual Review of Immunology 39, 449–479 (2021).
  133. 133Honda, K. & Littman, D. R. The microbiota in adaptive immune homeostasis and disease. Nature 535, 75–84 (2016).
  134. 134Brown, R. L., Sequeira, R. P. & Clarke, T. B. The microbiota protects against respiratory infection via GM-CSF signaling. Nat Commun 8, 1512 (2017).
  135. 135Dessein, R. et al. Antibiotic-related gut dysbiosis induces lung immunodepression and worsens lung infection in mice. Crit Care 24, 611 (2020).
  136. 136Zinter, M. S. et al. Pathobiological signatures of dysbiotic lung injury in pediatric patients undergoing stem cell transplantation. Nat Med 30, 1982–1993 (2024).
  137. 137Hagan, T., Cortese, M. & Rouphael, N. Antibiotics-driven gut microbiome perturbation alters immunity to vaccines in humans. Cell 178, 1313–1328 (2019).
  138. 138Theuretzbacher, U., Outterson, K., Engel, A. & Karlén, A. The global preclinical antibacterial pipeline. Nat Rev Microbiol 18, 275–285 (2020).
  139. 139Van Belkum, A. et al. Innovative and rapid antimicrobial susceptibility testing systems. Nat Rev Microbiol 18, 299–311 (2020).
  140. 140Murdoch, D. R. How best to determine causative pathogens of pneumonia. pneumonia 8, 1, s41479-016-0004-z (2016).
  141. 141Zeng, Z., Zhan, J., Zhang, K., Chen, H. & Cheng, S. Global, regional, and national burden of urinary tract infections from 1990 to 2019: an analysis of the global burden of disease study 2019. World Journal of Urology 40, 755–763 (2022).
  142. 142Yang, X. et al. Disease burden and long-term trends of urinary tract infections: A worldwide report. Frontiers in Public Health 10, 888205 (2022).
  143. 143Foxman, B. Recurring urinary tract infection: incidence and risk factors. American Journal of Public Health 80, 331–333 (1990).
  144. 144Ikäheimo, R. et al. Recurrence of urinary tract infection in a primary care setting: analysis of a 1-year follow-up of 179 women. Clinical Infectious Diseases 22, 91–99 (1996).
  145. 145Berry, S. H. et al. Prevalence of Symptoms of Bladder Pain Syndrome/Interstitial Cystitis Among Adult Females in the United States. Journal of Urology 186, 540–544 (2011).
  146. 146Sanyaolu, L. et al. Recurrent urinary tract infections and prophylactic antibiotic use in women: a cross-sectional study in primary care. Br J Gen Pract 74, e619–e627 (2024).
  147. 147Hooton, T. M. et al. A prospective study of risk factors for symptomatic urinary tract infection in young women. New England Journal of Medicine 335, 468–474 (1996).
  148. 148Scholes, D. et al. Risk factors for recurrent urinary tract infection in young women. Journal of Infectious Diseases 182, 1177–1182 (2000).
  149. 149Pinto, D. & Chronic UTI Australia. Hearing Patient Voices: Capturing the Impacts of Chronic Urinary Tract Infection. https://www.chronicutiaustralia.org.au/wp-content/uploads/2023/05/Hearing-Patient-Voices-Survey-Report.2023.pdf.
  150. 150Gaitonde, S., Christie, A. L., Garigipati, P., Alhalabi, F. & Zimmern, P. E. Very long-term outcomes after electrofulguration for antibiotic-refractory recurrent urinary tract infections in a predominantly menopausal cohort of women. The Journal of Urology 210, 649–658 (2023).
  151. 151Crivelli, J. J., Alhalabi, F. & Zimmern, P. E. Electrofulguration in the advanced management of antibiotic-refractory recurrent urinary tract infections in women. International Journal of Urology 26, 662–668 (2019).
  152. 152Ribeiro-Filho, L. et al. Complete fulguration of the trigone and bladder neck for antibiotic-refractory recurrent urinary tract infection. Neurourology and Urodynamics 42, 188–193 (2023).
  153. 153Yılmaz, U. et al. Efficacy of electrofulguration for women with antibiotic-refractory recurrent urinary tract infection. Urologia Internationalis 109, 494–500 (2025).
  154. 154Mulvey, M. A. et al. Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli. Science 282, 1494–1497 (1998).
  155. 155Kerkez, I., Tulkens, P. M., Tenson, T., Van Bambeke, F. & Putrinš, M. Uropathogenic Escherichia coli shows antibiotic tolerance and growth heterogeneity in an in vitro model of intracellular infection. Antimicrobial Agents and Chemotherapy 65, e01468-21 (2021).
  156. 156Mulvey, M. A., Schilling, J. D. & Hultgren, S. J. Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection. Infection and Immunity 69, 4572–4579 (2001).
  157. 157Schilling, J. D., Lorenz, R. G. & Hultgren, S. J. Effect of trimethoprim-sulfamethoxazole on recurrent bacteriuria and bacterial persistence in mice infected with uropathogenic Escherichia coli. Infection and Immunity 70, 7042–7049 (2002).
  158. 158Anderson, G. G. et al. Intracellular bacterial biofilm-like pods in urinary tract infections. Science 301, 105–107 (2003).
  159. 159Schwartz, D. J., Chen, S. L., Hultgren, S. J. & Seed, P. C. Population dynamics and niche distribution of uropathogenic Escherichia coli during acute and chronic urinary tract infection. Infection and Immunity 79, 4250–4259 (2011).
  160. 160Duraiswamy, S. et al. Purification of intracellular bacterial communities during experimental urinary tract infection reveals an abundant and viable bacterial reservoir. Infection and Immunity 86, e00740-17 (2018).
  161. 161Garofalo, C. K. et al. Escherichia coli from urine of female patients with urinary tract infections is competent for intracellular bacterial community formation. Infection and Immunity 75, 52–60 (2007).
  162. 162Kerrn, M. B., Struve, C., Blom, J., Frimodt-Møller, N. & Krogfelt, K. A. Intracellular persistence of Escherichia coli in urinary bladders from mecillinam-treated mice. Journal of Antimicrobial Chemotherapy 55, 383–386 (2005).
  163. 163Blango, M. G., Ott, E. M., Erman, A., Veranič, P. & Mulvey, M. A. Forced resurgence and targeting of intracellular uropathogenic Escherichia coli reservoirs. PLoS ONE 9, e93327 (2014).
  164. 164Mysorekar, I. U. & Hultgren, S. J. Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tract. Proceedings of the National Academy of Sciences 103, 14170–14175 (2006).
  165. 165Flores, C. et al. A human urothelial microtissue model reveals shared colonization and survival strategies between uropathogens and commensals. Science Advances 9, eadi9834 (2023).
  166. 166Lau, W. K. et al. Novel antibiotic-loaded particles conferring eradication of deep tissue bacterial reservoirs for the treatment of chronic urinary tract infection. Journal of Controlled Release 328, 490–502 (2020).
  167. 167Paduthol, G. et al. A microphysiological human mini-bladder reveals urine-urothelium interplay in tissue resilience and UPEC recurrence in urinary tract infections. Nature Communications https://doi.org/10.1038/s41467-026-68573-3 (2026) doi:10.1038/s41467-026-68573-3.
  168. 168Sharma, K. et al. Dynamic persistence of UPEC intracellular bacterial communities in a human bladder-chip model of urinary tract infection. eLife 10, e66481 (2021).
  169. 169Sharma, K. et al. Early invasion of the bladder wall by solitary bacteria protects UPEC from antibiotics and neutrophil swarms in an organoid model. Cell Reports 36, 109351 (2021).
  170. 170Elliott, T. S. J., Reed, L., Slack, R. C. B. & Bishop, M. C. Bacteriology and ultrastructure of the bladder in patients with urinary tract infections. Journal of Infection 11, 191–199 (1985).
  171. 171Gadhvi, J. G. et al. Bladder wall-embedded bacteria associated with increased risk of recurrence after electrofulguration in women with antibiotic-recalcitrant urinary tract infection. JU Open Plus 3, (2025).
  172. 172Pinato, D. J. et al. Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer. JAMA Oncol 5, 1774 (2019).
  173. 173Crespin, A. et al. A systematic review and meta-analysis evaluating the impact of antibiotic use on the clinical outcomes of cancer patients treated with immune checkpoint inhibitors. Front. Oncol. 13, 1075593 (2023).
  174. 174Chalabi, M. et al. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials. Annals of Oncology 31, 525–531 (2020).
  175. 175Cortellini, A. et al. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. J Immunother Cancer 9, e002421 (2021).
  176. 176Kim, C. G. et al. Prior antibiotic administration disrupts anti-PD-1 responses in advanced gastric cancer by altering the gut microbiome and systemic immune response. Cell Reports Medicine 4, 101251 (2023).
  177. 177Park, J. S. et al. Targeting PD-L2–RGMb overcomes microbiome-related immunotherapy resistance. Nature 617, 377–385 (2023).
  178. 178Gopalakrishnan, V. et al. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients. Science 359, 97–103 (2018).
  179. 179Merck & Co., Inc. Annual Report on Form 10-K for the Fiscal Year Ended December 31, 2024. https://www.sec.gov/Archives/edgar/data/310158/000162828025007732/mrk-20241231.htm (2025).
  180. 180Institute for Clinical and Economic Review. Treatment Options for Advanced Non-Small Cell Lung Cancer: Effectiveness, Value and Value-Based Price Benchmarks. https://icer.org/wp-content/uploads/2020/10/MWCEPAC_NSCLC_Evidence_Report_Plus_Supplement_101716.pdf (2016).
  181. 181Lurienne, L. et al. NSCLC Immunotherapy Efficacy and Antibiotic Use: A Systematic Review and Meta-Analysis. Journal of Thoracic Oncology 15, 1147–1159 (2020).
  182. 182Petrelli, F., Morelli, A. M., Luciani, A., Ghidini, A. & Solinas, C. Risk of Infection with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. Targ Oncol 16, 553–568 (2021).
  183. 183Ahmed, J. et al. Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors. OncoImmunology 7, e1507670 (2018).
  184. 184American Urological Association, Canadian Urological Association & Society of Urodynamics, F. P. M. and U. R. Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline. https://www.auanet.org/guidelines-and-quality/guidelines/recurrent-uti (2019).
  185. 185Stevens, D. L. et al. Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases 59, e10–e52 (2014).